Mapping the epigenome--impact for toxicology.
Recent advances in technological approaches for mapping and characterizing the epigenome are generating a wealth of new opportunities for exploring the relationship between epigenetic modifications, human disease and the therapeutic potential of pharmaceutical drugs. While the best examples for xenobiotic-induced epigenetic perturbations come from the field of non-genotoxic carcinogenesis, there is growing evidence for the relevance of epigenetic mechanisms associated with a wide range of disease areas and drug targets. The application of epigenomic profiling technologies to drug safety sciences has great potential for providing novel insights into the molecular basis of long-lasting cellular perturbations including increased susceptibility to disease and/or toxicity, memory of prior immune stimulation and/or drug exposure, and transgenerational effects.
Marlowe
Jennifer
J
Novartis Pharma AG, Investigative Toxicology, Preclinical Safety, Basel, Switzerland. jennifer.marlowe@novartis.com
Teo
Soon-Siong
SS
Chibout
Salah-Dine
SD
Pognan
François
F
Moggs
Jonathan
J
D000818:Animals; D064420:Drug-Related Side Effects and Adverse Reactions / Q000175:diagnosis / Q000235:genetics* / Q000517:prevention & control; D044127:Epigenesis, Genetic; D006801:Humans; D014116:Toxicology / Q000379:methods* / Q000639:trends